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Abstract
Tumor necrosis factor–related apoptosis-inducing li-
gand (TRAIL) can selectively kill tumor cells and, in
combination with other agents, could enhance tumor
therapy. We explored the combined therapeutic effects
of a secretable form of (S) TRAIL-induced apoptosis
and the downregulation of Bcl-2 in human gliomas.
We constructed a lentiviral delivery system: 1) for the
expression of short hairpin (sh) RNA to downregulate
Bcl-2 and for the expression of S-TRAIL to induce
apoptosis in glioma cells; and 2) to follow delivery
in vitro and the fate of tumors in real time in vivo.
We demonstrate that lentiviral-mediated simultaneous
downregulation of Bcl-2 and S-TRAIL–induced apop-
tosis leads to an increased expression of activated
caspase-3 and caspase-7, thus resulting in accel-
erated S-TRAIL–mediated apoptosis in glioma cells
in vitro. Using a highly malignant human glioma model
expressing EGFRvIII and firefly luciferase, we show
that the combined effect of Bcl-2 downregulation
and S-TRAIL–induced apoptosis results in complete
eradication of gliomas compared to S-TRAIL mono-
therapy. These results show that simultaneous trig-
gering of TRAIL-mediated death receptor pathway and
downregulation of Bcl-2 by shRNA leads to enhanced
eradication of gliomas and serves as a template in
developing and monitoring combination therapies for
the treatment of drug-resistant cancers.
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Introduction
Cancer cells are characterized by self-sufficiency in growth
signals, insensitivity to antigrowth signals, sustained angio-
genesis, tissue invasion andmetastasis, limitless replicative
potential, and evasion of apoptosis [1]. The molecular
mechanism of drug-induced apoptosis is associated with
mitochondrial dysfunction that is characterized by an in-
crease in mitochondrial membrane permeability and is reg-
ulated by Bcl-2 [2,3]. The overexpression of Bcl-2 in tumor
cells results in antiapoptotic effects triggered through the
extrinsic death receptor–dependent pathway [4], but not
the death receptor– independent pathway [5]. Targeted repres-
sion of Bcl-2 has the potential to facilitate tumor cell apoptosis
induced through a number of extrinsic apoptosis-inducing
agents, such as tumor necrosis factor– related apoptosis-
inducing ligand (TRAIL) [6,7], which offers one of the most
promising strategies in the field of death ligands and receptors.
Apoptosis initiated by TRAIL involves the binding of TRAIL
to death receptors DR4 and DR5, causing the intracellular
death domains of these receptors to trimerize [8–10]. Pre-
viously, we have engineered a secretable form of TRAIL (S-
TRAIL) consisting of an N-terminal fusion of the extracellular
domain of Flt3L, a ligand for Flt3 tyrosine kinase receptor, with
extracellular domain of TRAIL [9]. We have shown that
S-TRAIL has more potent apoptotic effects compared to TRAIL
itself, in addition to having a bystander effect for tumor cells
both in culture and in mouse models of glioma [10,11]. Recent
studies revealed that inhibitors of apoptosis (Bcl-2, XIAP, FLIP,
HDAC, or survivin) play an important role in mediating resis-
tance to the apoptotic effects of cytokines TRAIL and TNF-a in
melanoma cells [12,13]. Human gliomas overexpress Bcl-2,
which has been shown to induce complex changes in glioma
cell phenotype and protects glioma cells from various pro-
apoptotic stimuli [14,15].
A vital aspect to successful glioma therapy is to achieve
robust and prolonged transgene expression and to follow the
fate of tumors overtime. Recently, viral vectors have emerged
as an efficient method of integrating transgenes into the host
genome. In particular, lentiviral vectors have been used in
several studies to genetically modify cells ex vivo as these
viruses allow stable integration of transgenes into the host
genome irrespective of their state of division [16]. Several
approaches to imaging gene delivery and monitoring tumor
fate have been described [9,17,18]. Bioluminescent imaging
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offers high detection sensitivity, low background lumines-
cence from normal tissues, and rapid turnover of luciferase
substrates, making this method suited for temporal in vivo
imaging of gene expression [19].
In this study, we have engineered S-TRAIL lentiviral
vectors and have tested the combined potential of down-
regulating Bcl-2 by lentiviral-mediated expression of shRNA
and by induction of apoptosis by S-TRAIL, released from
transduced cells in a highly malignant EGFRvIII glioma
model. Furthermore, we have employed noninvasive real-
time imaging to follow changes in glioma burden in vivo. To
our knowledge, this is the first study to show the effect of
downregulating Bcl-2 by lentiviral-mediated shRNA in human
gliomas and following the combined effect of S-TRAIL (re-
leased within tumors) and Bcl-2 downregulation in real time
in vivo. The mode of combined cancer therapy described in
this study has three important advantages: 1) the use of
glioma cells stably expressing shRNA; 2) the use of an en-
hanced apoptosis-inducing recombinant S-TRAIL with a by-
stander effect; and 3) real-time imaging of glioma burden
in vivo. This study should immensely help in developing
clinically relevant combination therapies in vivo.
Methods
Generation of Lentiviral Vectors
Short hairpin (sh) RNA plasmid constructs for Bcl-2 and
green fluorescent protein (GFP) were constructed in pSuper
vector (Oligoengine, Seattle, WA) to include the specific
19-bp target sequence for the shBcl-2 construct (5V-TGT-
GGATGACTGAGTACCTGA-3V) [14] and the shGFP con-
struct (5V-GAACGGCATCAAGGTGAAC-3V) [20] in front of
the H1 RNA polymerase III promoter, resulting in pSuper-
shBcl-2 and pSuper-shGFP. H1 promoter shBcl-2 or shGFP
fragments were amplified from pSuper vectors using poly-
merase chain reaction and cloned into CSCRW [derived from
CSCGW [21] lentiviral (LV) vector in which GFP sequences
were replaced by DsRed2 cDNA sequences], resulting in
LV-shBcl-2 and LV-shGFP lentiviral vectors. All constructs
were verified by sequencing secretable form of TRAIL
(S-TRAIL), which was created by fusing the coding se-
quences for the extracellular domain of Flt3L, and an iso-
leucine zipper with the N-terminal of TRAIL [9] was placed
under a Cytomegalovirus (CMV) promoter in a vector coex-
pressing GFP through an internal ribosomal entry sequence
(IRES), thus resulting in an LV-S-TRAIL construct. Similarly,
cDNA sequences for firefly luciferase (Fluc) were placed
under the CMV promoter in a vector coexpressing LacZ
through IRES, resulting in the LV-Fluc construct. For a de-
tailed description of lentivirus vector production, see Sena-
Esteves et al. [21]. In brief, lentiviral genome (CMVR8.91)
was transfected into 293T cells together with an envelope-
coding plasmid (VSVG) and vector constructs. LVs were
harvested 40 hours posttransfection and concentrated by
ultracentrifugation. Titers were determined on 293T cells as
transducing units using serial dilutions of vector stocks with
8 mg/ml polybrene (Sigma Chemical, St. Louis, MO).
Generation of shBcl-2–Expressing Glioma Cells
Human glioma lines U87, U-251, Gli36, and Gli36-EGFR-
vIII (stably expressing the mutant form of EGFR associated
with a high malignancy of this tumor type) [19,20] and 293T
cells were grown in Dulbecco’s modified Eagle’s medium
with 10% fetal bovine serum (Sigma) at 37jC in a humidified
atmosphere with 5% CO2 and 1% penicillin/streptomycin
(Invitrogen, Grand Island, NY). Different adherent glioma
cell lines were transduced with LV-shBcl-2 or LV-shGFP at
multiplicities of infection (MOI) ranging from 1 to 3, and the
cells were visualized for DsRed2 expression by fluorescence
microscopy. Transduction was carried out for 12 hours at
37jC in the presence of polybrene (8 mg/ml; Sigma). Bcl-2
levels were measured by Western blot analysis 5 days after
transduction, as described below. Gli36-EGFRvIII glioma
cells were also transduced with LV-Fluc at an MOI of 3;
72 hours later, cells were incubated in a medium containing
150 mg/ml D-luciferin (Biotium, Hayward, CA), and bio-
luminescence imaging was performed as described below.
S-TRAIL Western Blot Analysis, Enzyme-Linked
Immunosorbent Assay (ELISA), and Immunocytochemistry
Human Gli36-EGFRvIII glioma cells and 293T cells were
transduced with LV-S-TRAIL vector at an MOI of 1; 36 hours
later, a culture medium and the cells were harvested. Pro-
teins were isolated from harvested cells, resolved by sodium
dodecyl sulfate–polycrylamide gel electrophoresis (SDS-
PAGE), and immunoblotted with anti-TRAIL (ProScience,
Poway, CA) and anti–cleaved PARP (Cell Signaling, Bev-
erly, MA) antibodies. S-TRAIL concentration in the condi-
tioned culture medium was measured by ELISA with the
TRAIL Immunoassay Kit (Biosource International, Camarillo,
CA) according to the manufacturer’s protocol, using re-
combinant human TRAIL expressed in Escherichia coli as
a standard. Different glioma lines were plated in 96-well
plates with five replicate wells and incubated with varying
concentrations (0–250 ng/ml) of S-TRAIL obtained from
transduced 293T cells. Twenty-four hours later, glioma cell
viability was determined as described below. Gli36-EGFRvIII
glioma cells were incubated with 80 ng/ml S-TRAIL; 24 hours
later, cells were fixed, permeabilized, and incubated with a
cleaved caspase-3 antibody (1:100; Cell Signaling) for 1 hour
at 37jC. Cells were then washed and incubated with goat
anti–rabbit Alexa dye (540 nm)–conjugated secondary an-
tibody (Molecular Probes, Eugene, OR) for 1 hour, washed
again, mounted, and examined by fluorescence microscopy.
Cytochrome c and BH3-Interacting Domain Death Agonist
(BID) Immunoblotting
For assessing the combined effect of S-TRAIL and Bcl-2
downregulation, an S-TRAIL concentration of 40 ng/ml was
used. Gli36-EGFRvIII-shGFP and Gli36-EGFRvIII-shBcl-2
cells were incubated with S-TRAIL (40 ng/ml) for 24 hours,
and the total cytochrome c in mitochondrial fractions was ana-
lyzed by using cytochrome c assay kit (Calbiochem,
San Diego, CA) according to the manufacturer’s protocol.
Briefly, 5  106 of Gli36-EGFRvIII-shGFP and Gli36-
EGFRvIII-shBcl-2 cells with or without S-TRAIL treatment
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was harvested by centrifugation at 700g for 5 minutes. After
washes with phosphate-buffered saline (PBS), the cells
were resuspended in a 250-ml extraction buffer containing
a protease inhibitor mixture and dithiothreitol, and then incu-
bated on ice for 10 minutes, homogenized, and centrifuged
at 700g for 10 minutes at 4jC. Supernatant was collected
and further centrifuged at 10,000g for 30 minutes at 4jC.
Resulting supernatants were harvested and designated
as cytosolic fractions, and pellets were resuspended in an
appropriate buffer and designated as mitochondrial frac-
tions. Cytochrome c was analyzed using Western blot analy-
sis with cytochrome c monoclonal antibody (Calbiochem)
or control antibody against tubulin. Mitochondrial fractions
were resolved by SDS-PAGE, transferred to membranes,
and immunoblotted with rabbit anti-BID antibody (Cell Sig-
naling, Cambridge, MA).
Caspase-3/7 and Cell Viability Assay
Different glioma lines either expressing shBcl-2 or shGFP
were plated at 1  104 cells/well in 96-well plates with five
replicate wells for each condition. Cells were either left
untreated or treated with 40 ng/ml S-TRAIL for 24 hours,
and the metabolic activity of the cells was determined using a
luminescent adenosine triphosphate (ATP)–based assay
(CellTiter GLO; Promega, Madison, WI), according to the
manufacturer’s instructions. Results were read with a lumin-
ometer with a read time of 1 second/well. Glioma cells were
also plated as described above, incubated with 40 ng/ml
S-TRAIL for 24 hours, and analyzed using ApoONE Homo-
geneous Caspase 3/7 Assay (Promega), according to the
manufacturer’s instructions. Samples were read after 1 hour
of incubation with the caspase substrate, as described
above. S-TRAIL–treated cells were analyzed for viability
by luminescent ATP-based assay (CellTiter GLO; Promega)
24 hours later, as described above.
Tumor Models and Glioma Implantations
Athymic nude mice (nu/nu, 6–7 weeks old; Charles River
Laboratories, Wilmington, MA) were anesthetized by an
intraperitoneal injection of a mix of ketamine (1.6 mg/mice)
and xylazine (240 mg/mice) in saline. For correlation studies,
different concentrations of Gli36-EGFRvIII-Fl cells (ranging
from 5  104 to 5  106; n = 2 tumors for each cell number)
were implanted subcutaneously, and the mice were imaged
for Fluc activity 24 hours later, as described below. For
assessing the effect of Bcl-2 downregulation and S-TRAIL
on glioma proliferation, we employed our previously devel-
oped model of assessing the bystander effect of S-TRAIL
released within the tumor [10]. Gli36-EGFRvIII-shBcl-2-Fluc
or Gli36-EGFRvIII-shGFP-Fluc glioma cells (Gli36-EGFR-
vIII-Fl cells transduced with either LV-shBcl-2 or LV-shGFP)
in midlog phase were harvested by trypsinization, and single-
cell suspensions were transduced with LV-S-TRAIL at an
MOI of 1 for 6 hours at 37jC. S-TRAIL–transduced cells
were washed with PBS, and mice were implanted with:
1) Gli36-EGFRvIII-Fl-shBcl-2; 2) Gli36-EGFRvIII-Fl-shGFP;
3) a mix of 1.5 106 of S-TRAIL–transduced cells and 6.0
106 of Gli36-EGFRvIII-Fl-shBcl-2 cells; and 4) a mix of 1.5 
106 of S-TRAIL–transduced cells and 6.0  106 of Gli36-
EGFRvIII-Fl-shGFP cells, in the two opposite flanks of the
mice (n = 10 tumors in each case). Three days after glioma
cell implantations, mice were imaged for Fluc activity, as
described below. All animal protocols were approved by an
institutional review board.
Bioluminescence Imaging in Culture and In Vivo
Fluc-bearing glioma cells were incubated with 150 mg/ml
D-luciferin and assayed for luciferase activity using a liquid
nitrogen charged cooled device (CCD; Roper Scientific,
Trenton, NJ). Mice were given an intraperitoneal injection
of D-luciferin (4.5 mg/25 g body weight; prepared in 150 ml
of saline) and imaged for Fluc activity for 1 minute after
D-luciferin administration using a cryogenically cooled high-
efficiency CCD camera system (Roper Scientific). Mice were
imaged for Fluc activity on the fourth, sixth, and eighth days
after tumor implantation. Postprocessing and visualization
were performed as described previously [22].
Tissue Processing and Immunohistochemistry
Two hours following the last luciferase imaging session,
mice were sacrificed, tumor tissues were fixed in 10% buff-
ered formalin and embedded in paraffin, and 6-mm sec-
tions were cut on a cryostat (CM 3000; Leica Microsystems
[Wetzlar, Germany]). The sections were dehydrated in xy-
lene and ethanol then immersed in PBS, and caspase-3
staining was performed according to the manufacturer’s pro-
tocol using caspase-3 immunostaining kit (Cell Signaling).
Immunostained sections were also stained with hematoxylin
and eosin.
Statistical Analysis
Data are expressed as mean ± SEM and were analyzed
by either Student’s t test or analysis of variance (after
Bartlett’s test of homogeneity of variance), followed by
Newman-Keuls correction for multiple comparisons. Differ-
ences were considered significant at P < .05.
Results
The plasmid constructs used to generate lentivirus vectors
(LVs) in this study are diagrammed in Figure 1A. To deter-
mine the transduction efficiency of these LVs, 293Tand Gli36
glioma cells were transduced and visualized for DsRed2 and
GFP fluorescence. The presence of 90% to 95% DsRed2-
positive and GFP-positive glioma cells revealed the high
transduction efficiency of LVs (Figure 1B). Gli36-EGFRvIII
human glioma cells were transduced with LV-S-TRAIL;
24 hours after transduction, total protein was isolated from
tumor cells, fractionated by denaturing SDS-PAGE, and
immunoblotted using antiserum against TRAIL. Immuno-
reactive proteins corresponding to the size of S-TRAIL were
present in the respective LV-S-TRAIL–transduced cells and
not in control vector–transduced cells (Figure 2A). Quanti-
tation of TRAIL in the cell supernatant confirmed the se-
cretion of 230 ng/106 cells per 24 hours by glioma cells
transduced with LV-S-TRAIL, with no significant amounts
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produced by nontransduced or control vector–transduced
cells (Figure 2B). Cell viability assays on different glioma cell
lines treated with varying concentrations of S-TRAIL re-
vealed that both Gli36 and Gli36-EGFRvIII are more sus-
ceptible to S-TRAIL–mediated cell killing than are U251 and
U87 glioma cells (Figure 2C). Immunocytochemistry and
immunoblotting with antibodies detecting cleaved caspase-
3 (Figure 2D) and cleaved PARP (Figure 2A) respectively
revealed that lentivirally expressed S-TRAIL induced apop-
tosis in glioma cells. These results show that TRAIL secreted
by lentiviral-transduced cells is active and can induce apop-
tosis in glioma cells in culture.
To test whether shBcl-2 could effectively knock down
protein levels of Bcl-2 in glioma cells, Gli36-EGFRvIII glioma
cells were transduced with LV-shBcl-2 and control LV-shGFP,
with MOI ranging from 1 to 3, and the levels of Bcl-2 protein
were then determined by immunoblotting after 5 days of
transduction using antiserum against Bcl-2. Immunoreactive
proteins corresponding to the size of Bcl-2 were present in the
respective LV-shGFP–transduced cells and not in LV-shBcl-
2–transduced cells (Figure 3A). The other well-established
glioma lines U87 and U251 showed a similar downregulation
of Bcl-2 when transduced with shBcl-2 lentiviral vectors
(Figure 3B). Viability assays revealed a 25% to 30% reduc-
tion in cell viability over a 24-hour period in cells expressing
shBcl-2 compared to glioma cells expressing shGFP (Fig-
ure 3C). As all the glioma lines tested showed a similar
decrease in cell viability, we used Gli36-EGFRvIII glioma cells
for further studies, as EGFRvIII expression in gliomas has
been previously reported to enhance tumor growth [23]. Next,
we investigated whether the combined effect of S-TRAIL and
Bcl-2 downregulation would influence the viability of glioma
cells in culture. Gli36-EGFRvIII glioma cells were transduced
with LV-S-TRAIL with an MOI of 1; 24 hours later, the medium
was collected and quantified by ELISA. Both shGFP and
shBcl-2–expressing glioma cells were incubated with a me-
dium from LV-S-TRAIL–transduced cells (40 ng /ml) and
assessed for caspase-3 activity, cytochrome c release, BID
cleavage, and cell viability. At 24 hours, a significantly higher
(P < .02) caspase-3/7 activity was assessed in shBcl-2–
expressing glioma cells compared to shGFP-expressing cells
(Figure 4A). A considerably reduced expression of the 22-kDa
BID protein indicating its cleavage was observed in S-TRAIL–
treated shBcl-2–expressing cells than in shGFP-expressing
glioma cells (Figure 4B). Higher levels of cytochrome c were
Figure 1. shRNA, S-TRAIL, and Fluc lentiviral vectors. (A) A self-inactivating
lentiviral system based on HIV-1 (CS-CG) [36] was used to construct vectors
(i) expressing shRNAagainst humanBcl-2 andGFP underHI RNA polymerase
III promoter andDsRed2 under theCMVpromoter; and (ii) expressing S-TRAIL
or Fluc under the CMV promoter with an IRES sequence followed by GFP and
LacZ, respectively. (B) Human glioma, Gli36-EGFRvIII, U251, and U87 cells
transduced in culture with LV-shBcl-2 and 293T cells transduced with LV-S-
TRAIL at an MOI of 1 were visualized for DsRed2 or GFP fluorescence.
Original magnification, 10 (B).
Figure 2. S-TRAIL– induced apoptosis and bystander effect in human glioma
cells. (A) Gli36-EGFRvIII glioma cells were transduced with LV-S-TRAIL
vector or control vector bearing only IRES-GFP under the CMV promoter;
24 hours after transduction, the cells were harvested, and proteins were
resolved by SDS-PAGE and immunoblotted with antibodies against TRAIL
and anti – cleaved PARP. Lane 1: S-TRAIL– transduced cell lysates. Lane 2:
Control vector – transduced cell lysates. (B) Immunoreactive S-TRAIL protein
concentration in the medium of transduced cells, as determined by ELISA.
(C) Different glioma lines were plated in 96-well plates with five replicate wells
and incubated with varying concentrations (0–250 ng/ml) of S-TRAIL for
24 hours, and glioma cell viability was determined by using a luminescent
ATP-based assay. (D) Gli36-EGFRvIII glioma cells were incubated with
80 ng/ml S-TRAIL; 24 hours later, immunohistochemistry was performed with
anti –cleaved caspase-3 antibody: (a) S-TRAIL– incubated cells, and (b)
control-incubated cells. Original magnification, 20 (B).
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present in mitochondrial fractions of untreated shBcl-2 glioma
cells compared to S-TRAIL–treated shBcl-2 glioma cells
(Figure 4C). Furthermore, cell viability in shBcl-2–expressing
and shGFP-expressing gliomas treated with S-TRIAL was
significantly lower (P < .02) in shBcl-2–expressing cells than
in shGFP cells (Figure 4D). These results strongly suggest
that downregulation of Bcl-2 sensitizes EGFRvIII-expressing
glioma cells to S-TRAIL–mediated apoptosis.
To monitor the therapeutic efficacy of S-TRAIL in vivo,
Gli36-EGFRvIII cells were transduced with LV-Fluc, and the
resulting Gli36-EGFRvIII-Fl cells were shown to retain the
same proliferative capacity as Gli36-EGFRvIII glioma cells
(Figure 5A). Different concentrations of Gli36-EGFRvIII-Fl
cells (ranging from 5  104 to 5  106) were implanted sub-
cutaneously, and mice were imaged for Fluc activity 24 hours
later. Bioluminescent signal correlated linearly with the
number of implanted Gli36-EGFRvIII-Fl cells in the ranges
tested (Figure 5B), thus allowing the quantification of cells
in vivo in mouse models of glioma. To demonstrate the effect
of Bcl-2 downregulation on S-TRAIL–mediated apoptosis
in vivo, we also transduced Gli36-EGFRvIII-Fl–expressing
shGFP or shBcl-2 glioma cells in culture with LV-S-TRAIL,
mixed 20% of LV-S-TRAIL–transduced cells with 80% of
Gli36-EGFRvIII-Fl cells, and implanted them subcutaneously
into nude mice. The combined effect of Bcl-2 downregula-
tion and S-TRAIL secreted by transduced cells on tumor
growth was followed by Fluc bioluminescence imaging on
days 4, 6, and 8 after implantation (Figure 5C). A signifi-
cant decrease in Fluc signal was seen as early as day 4 (P <
.02) in shBcl-2–downregulated gliomas; on day 8, the
tumors were eradicated in shBcl-2–downregulated gliomas
compared to shGFP-downregulated controls treated with
S-TRAIL. The results show that downregulation of Bcl-2
and subsequent S-TRAIL treatment result in a substantial
decrease in tumor growth compared to implanted tumors
with intact Bcl-2 (Figure 5D).
To verify whether S-TRAIL induced the upregulation
of caspase-3 in glioma cells, we also performed cleaved
caspase-3 staining on shBcl-2 and control tumor sections. A
majority of glioma cells in the periphery of the tumor were
cleaved caspase-3–positive (Figure 6, A–D), indicating the
induction of apoptosis by secreted S-TRAIL from the 20%
LV-S-TRAIL– implanted cells. Immunostaining revealed a
higher number of cleaved caspase-3–positive cells in Bcl-2–
downregulated gliomas than in control gliomas (Figure 6E).
Discussion
In this study, we have engineered lentiviral vectors with
shRNA, apoptosis-inducing agents, and in vivomarker genes,
and we have shown that downregulation of antiapoptotic
Bcl-2 enhances apoptosis mediated by S-TRAIL in a malig-
nant model of glioma both in vitro and in vivo. Furthermore,
we demonstrate that the enhanced apoptosis-inducing
ability in Bcl-2–downregulated gliomas can be followed in
real time by bioluminescence imaging in live animals.
There is emerging evidence that supports the role of key
proteins in controlling cell proliferation, apoptosis, and an-
giogenesis in the pathogenesis and progression of cancer
[24]. Among these proteins, Bcl-2 has been regarded as a
potential therapeutic target on the basis of its ability to disrupt
apoptosis and to confer resistance to chemotherapy and
radiotherapy in cancer cells [12,25–28]. Human glioma cells
express a variety of antiapoptotic and proapoptotic Bcl-2
family proteins [29], and overexpression of Bcl-2 has been
shown to induce complex changes in glioma cell phenotype
in that it not only protects glioma cells from various pro-
apoptotic stimuli [30] but also enhances their motility [31]. We
Figure 4. Combined effect of the downregulation of Bcl-2 and S-TRAIL on
glioma cells. (A) Gli36-EGFRvIII glioma cells expressing shBcl-2 or shGFP
were treated with 40 ng/ml TRAIL; 24 hours later, caspase-3 and caspase-7
activity was determined by using ApoONE Homogeneous Caspase 3/7 Assay.
(B) S-TRAIL– treated cells were harvested, and proteins were resolved by
SDS-PAGE and immunoblotted with anti-BID antibody. (C) Cytochrome c
assays were performed on S-TRAIL– treated cells by isolating mitochondrial
fractions resolving the proteins by SDS-PAGE and immunoblotting by anti –
cytochrome c antibody. (D) Gli36-EGFRvIII glioma cells expressing shBcl-2
or shGFP were treated with 40 ng/ml TRAIL; 16 hours later, cell viability was
determined by using a luminescent ATP-based assay (*P < .02).
Figure 3. Downregulation of Bcl-2 using lentiviral-delivered shRNA against
Bcl-2. (A) Gli36-EGFRvIII glioma cells were transduced with LV-shBcl-2 or
LV-shGFP with different MOI ranging from 1 to 3, and cells were harvested
5 days after transduction. Proteins were resolved by SDS-PAGE and
immunoblotted with anti –Bcl-2 and anti –a-tubulin antibodies. (B) U87 and
U251 glioma cells were transduced with LV-shBcl-2 or LV-shGFP at an MOI of
3 and harvested after 5 days. Proteins were resolved and blotted as in (A). (C)
Different glioma lines were plated; 24 hours later, cell viability was determined
using a luminescent ATP-based assay.
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have employed shRNA to inhibit Bcl-2 gene expression as
they show features superior to those of antibodies and
inhibitors, in part because they are easily applicable to their
target, including intracellular factors and even transcription
factors. Furthermore, they promise potent gene inhibition
with exquisite selectivity, even down to the level of single-
nucleotide polymorphisms [32]. Our Bcl-2 immunoblotting
results reveal that there is no downregulation of Bcl-2 at an
MOI of 1; with higher MOI, this downregulation is specific
and significant, and influences the proliferation capacity of
the cells. Our findings on the effect of S-TRAIL on Bcl-2–
downregulated glioma cells are in line with those of other
studies showing the added effect of Bcl-2 downregulation with
chemotherapy in vitro and in vivo in other cell types, including
non-Hodgkin’s lymphoma, Epstein-Barr virus–associated
lymphoproliferative disease, malignant melanoma, prostate
carcinoma, renal carcinoma, non–small cell lung carcinoma,
breast carcinoma, and gastric carcinoma [3].
The use of death ligands for tumor therapy in animal
models supports their potential for use in the clinical setting.
TRAIL, a type II transmembrane protein, has become an
attractive molecule for the treatment of cancers because of
its potential to specifically kill tumor cells [8,33]. For effi-
cient tumor therapy, it is important that the tumor cells
producing the therapeutic protein not only undergo apop-
tosis by themselves but also induce apoptosis in surrounding
cells. For this purpose, we have engineered a secretable
version of TRAIL [9] and have shown that this form of TRAIL
(S-TRAIL) has more potent apoptotic effects both in vitro
and in vivo [9,10,34]. In this study, we have treated Bcl-2–
downregulated gliomas with S-TRAIL and have shown that
these gliomas have a significantly enhanced induction of
apoptosis both in culture and in vivo. We [10,19,22] and
others [35–37] have shown that intratumoral delivery of
TRAIL has antitumor activity but requires multiple injec-
tions to have an antitumor effect [22]. To circumvent the
use of multiple injections and to quantify the subtle changes
in tumor growth in S-TRAIL–treated gliomas expressing
shBcl-2, we implanted a mix of a defined number of LV-S-
TRAIL–transduced glioma cells and nontransduced cells.
LV-S-TRAIL–transduced cells produce S-TRAIL within the
tumor and induce apoptosis in surrounding tumor cells. The
production of S-TRAIL within the tumor allows to quanti-
tate differences between Bcl-2–downregulated and control
GFP-downregulated gliomas in vivo. In this study, we have
shown that 20% of TRAIL-expressing cells in gliomas is able
to significantly reduce tumor burden in Bcl-2–downregulated
gliomas in vivo.
The limited availability of noninvasive imaging methods
to monitor molecular events has been one of the main
Figure 5. Enhanced S-TRAIL– induced apoptosis in Bcl-2–downregulated gliomas in vivo. (A) Gli36-EGFRvIII and Gli36-EGFRvIII-Fl cells were grown in culture,
and growth over time was compared. (B) Different concentrations of Gli36-EGFRvIII-Fl cells were implanted subcutaneously; 24 hours later, mice were injected
intraperitoneally with D-luciferin and imaged for Fluc activity, and the co-relation between the number of implanted cells and photon intensity was plotted. (C) Mice
bearing subcutaneous gliomas: (i) Gli36-EGFRvIII-Fl-shGFP, (ii) Gli36-EGFRvIII-Fl-shBcl-2, (iii) Gli36-EGFRvIII-Fl-shGFP-S-TRAIL, and (iv) Gli36-EGFRvIII-Fl-
shBcl-2-S-TRAIL were injected intraperitoneally with D-luciferin and imaged for Fluc activity on days 4, 6, and 8 after implantation. One representative mouse from
each group is shown, and each image represents a scan time of 1 minute. A pseudocolor image represents the spatial distribution of photon counts produced by
active luciferase within the tumor (D). Fluc bioluminescence intensity of tumors over time, given as the average of tumors in 10 animals, is shown (*P < .02).
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limitations in testing the efficacy of various tumor therapy
paradigms. In our previous studies, we have shown that we
can quantify glioma burden in vivo using noninvasive bio-
luminescence imaging [22,34]. In the present study, we
further demonstrate the sensitivity of luciferase-based bio-
luminescence imaging and show that we can follow the effect
of S-TRAIL on Bcl-2–downregulated gliomas in real time,
thus allowing us to quantify the combined effects of Bcl-2
downregulation and the induction of apoptosis by S-TRAIL.
Furthermore, the presence of activated caspase-3–positive
cells reveals the induction of apoptosis in gliomas through
the S-TRAIL–mediated pathway. Most of the glioma is
necrotic, except for cells in the tumor border that are still
undergoing apoptosis and those cells to which the anti–
cleaved caspase-3 antibody binds. The apoptotic process is
a dynamic continuum of specific molecular events, and it
is difficult to quantitate significant changes in caspase-3
activation between shBcl-2–downregulated and shGFP-
downregulated gliomas at a particular time point.
In conclusion, we show that downregulation of Bcl-2 using
lentivirally delivered shRNA enhances the apoptosis of gli-
oma cells by S-TRAIL both in vitro and in vivo. The enhanced
apoptosis in Bcl-2–downregulated gliomas can be moni-
tored in real time by bioluminescence imaging in live ani-
mals. The engineering of clinically approved viral vectors
expressing regulatable versions of S-TRAIL and shBcl-2 will
be highly useful in tuning up this therapeutic approach.
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